EGFR and neoplasm: Both screens identified ALK as the most effective combination target (Fig. 2F,G and Fig. S3F), altogether demonstrating that partial sensitivity to ALKi primary tumor cells was regulated by EGFR and PI3Kβ and could be effectively overcome by combined inhibition of ALK and EGFR or PI3Kβ.